Acute cardiac care & resuscitation
Haemodynamic Effects of Istaroxime in SCAI Stage B HF-Related Cardiogenic Shock: Insights from the SEISMiC Trial
Authors' conclusion
In patients with ADHF-pre-CS, istaroxime at doses up to 1.0 μg/kg/min for up to 60 h was associated with sustained improvements in measures of LV performance (API and LVSWI), in parallel with increase in PA compliance and reduction in PA elastance at 48 h. As compared with placebo, istaroxime improved LV contractility and preserved RV contractility, which deteriorated on placebo, over time.
Study context
- Population
- Patients with acute decompensated heart failure (ADHF)-related SCAI stage B cardiogenic shock (CS)randomized
- Participants
- 30 patients
- Comparison
- istaroxime- vs placebo-treated patients
- istaroximen = 19
- placebon = 11
Methodological detailsSEISMiC extension study, randomized
- SEISMiC extension study
- Randomized
Primary result
As reported in the abstract
- Greater increases in aortic pulsatility index (API) and LVSWI with istaroxime compared with placebo
Further findings
Pulmonary artery (PA) compliance and PA elastance · 48 h
- Greater increase in PA compliance and reduction in PA elastance with istaroxime compared with placebo
Group-averaged pressure-volume (PV) loop analysis: Left ventricular (LV) and right ventricular (RV) contractility · over time
- Placebo: LV contractility remained stable and RV contractility tended to deteriorate
- Istaroxime: LV contractility improved and RV contractility tended to be stabilized
LV Ees and RV Ees · baseline to 48 h
- Greater increases in both LV Ees and RV Ees with istaroxime versus placebo
Original publication
Summarised from the published abstract; every number is checked against it